Related Experiment Video
Updated: Jul 7, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
TREK-1 is a novel molecular target in prostate cancer
Iryna Voloshyna1, Alessandra Besana, Mireia Castillo
1Department of Pharmacology, Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York 10032, USA.
Abstract:
TREK-1 is a two-pore domain (K(2P)) potassium channel that carries a leak current that is time- and voltage-independent. Recently, potassium channels have been related to cell proliferation and some K(2P) family channels, such as TASK-3, have been shown to be overexpressed in specific neoplasms. In this study, we addressed the expression of TREK-1 in prostatic tissues and cell lines, and we have found that this potassium channel is highly expressed in prostate cancer but is not expressed in normal prostate nor in benign prostatic hyperplasia. Furthermore, expression of TREK-1 correlates strongly with the grade and the stage of the disease, suggesting a causal link between channel expression and abnormal cell proliferation. In vitro studies showed that TREK-1 is highly expressed in PC3 and LNCaP prostate cancer cell lines but is not detectable in normal prostate epithelial cells (NPE). In this report, we show that overexpression of TREK-1 in NPE and Chinese hamster ovary (CHO) cells leads to a significant increase in proliferation. Moreover, the increased cell proliferation rate of PC3 cells and TREK-1 overexpressing CHO cells could be reduced when TREK-1 current was reduced by overexpression of a dominant-negative TREK-1 mutant or when cells were exposed to a TREK-1 inhibitor. Taken together, these data suggest that TREK-1 expression is associated with abnormal cell proliferation and may be a novel marker for and a molecular target in prostate cancer.
Insights
TREK-1 potassium channels are highly expressed in prostate cancer, driving abnormal cell proliferation. Inhibiting TREK-1 may offer a new therapeutic target for prostate cancer treatment.
Area of Science:
- Molecular Biology
- Oncology
- Physiology
Background:
- Potassium channels, specifically two-pore domain (K2P) channels, are implicated in cell proliferation.
- Some K2P channels, like TASK-3, are overexpressed in neoplasms, suggesting a role in cancer.
Purpose of the Study:
- To investigate the expression of TREK-1 in prostate tissues and cell lines.
- To determine the role of TREK-1 in prostate cancer cell proliferation.
Main Methods:
- Quantitative analysis of TREK-1 expression in normal prostate, benign prostatic hyperplasia, and prostate cancer tissues.
- In vitro studies using prostate cancer cell lines (PC3, LNCaP) and normal prostate epithelial cells (NPE).
- Functional assays involving TREK-1 overexpression, dominant-negative mutants, and pharmacological inhibitors.
Main Results:
- TREK-1 is highly expressed in prostate cancer but not in normal or benign prostate tissues.
- TREK-1 expression correlates with advanced disease grade and stage.
- Overexpression of TREK-1 significantly increases proliferation in NPE and CHO cells.
- Inhibition of TREK-1 activity reduces proliferation in prostate cancer cells.
Conclusions:
- TREK-1 expression is associated with abnormal cell proliferation in prostate cancer.
- TREK-1 may serve as a novel biomarker for prostate cancer.
- TREK-1 represents a potential molecular target for prostate cancer therapy.
More Related Videos
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
07:48Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...